BACKGROUND: Myocarditis is a rare but significant adverse event associated with COVID-19 vaccination, especially for males under 40. If the risk of myocarditis is not stratified by pertinent risk factors, it may be diluted for high-risk and inflated for low-risk groups. We sought to assess how the risk of myocarditis is reported in the literature. METHODS: In accordance with PRISMA standards we reviewed primary publications in PubMed, Embase, Google Scholar, and MedRxiv (through 3/2022) and included studies that estimated the incidence of myocarditis/pericarditis after receiving either the BNT162b2 (Pfizer), mRNA-1273 (Moderna), or Ad26COVS1 (Janssen) vaccine. The main outcome was the percentage of studies using 4, 3, 2, 1, or 0 stratifiers (i.e., sex, age, dose number, manufacturer) when reporting the highest risk of myocarditis. Secondary outcomes included the incidence of myocarditis in males after dose 1 and 2 of the BNT162b2 (Pfizer) or mRNA-1273 (Moderna) vaccine. RESULTS: The 29 included studies originated in North America, Europe, Asia, or were Worldwide. Of them, 28% (8/29) used all 4 stratifiers, and 45% (13/29) used 1 or 0 stratifiers. The highest incidence of myocarditis ranged from 8.1-39 cases per 100,000 persons (or doses) in studies using 4 stratifiers. Six studies reported an incidence greater than 15 cases per 100,000 persons (or doses) in males aged 12-24 after dose 2 of an mRNA-based vaccine. CONCLUSIONS: Only 1 in 4 articles reporting myocarditis used 4 stratifiers, and males younger than 40 receiving a second dose of an mRNA vaccine are at greatest risk.
- All age groups
- COVID-19
- Safety
